I would like to congratulate our ranking member, Mr. Pallone, for moving up to ranking member of the full committee.
Joe Pitts
The Public Record
Joseph R. Pitts is a former Republican member of the U.S. House of Representatives, serving Pennsylvania's 16th congressional district from 1997 to 2017. During his tenure, Pitts was known for his focus on healthcare, energy, and family issues, often advocating for conservative policies. He played a significant role in various legislative efforts, including those related to the Affordable Care Act and energy independence. Pitts was also involved with the Pennsylvania Family Institute, reflecting his commitment to family values and social issues.
We have seen this administration casually ignore the law when it comes to immigration, EPA regs, and ObamaCare. Now, we are going to see whether they ignore the law when it comes to forcing churches in California to pay for abortion. For…
Jonathan Gruber, ``smart'' MIT professor, ObamaCare architect, who has had to apologize for repeatedly calling the American voters stupid, has received millions of taxpayer dollars from Federal and State governments. He now has an…
I just want to point out to the committee that there were calls back about a month or two ago of distributing the vaccine widely in West Africa without a control group, had we done that, the downturn in Liberia now would have been…
``Lack of transparency is a huge political advantage. Call it the stupidity of the American voter or whatever.'' That was ObamaCare architect Jonathan Gruber speaking last year at the University of Pennsylvania. The broken ObamaCare…
Antimicrobial resistance (AMR) is an increasingly serious threat to global public health.
GAIN did not fully fix the problem, and much more is needed if we are to incentivize the type of drug development needed to combat this global threat.
We must preserve those antibiotics critical to human health for use in treating disease--not for growth promotion or disease prevention.
GAIN didn't fully fix the problem and much more is needed if we are to incentivize the type of drug development needed.
Do you believe that we need to further incentivize new drug and diagnostic development if we are to appropriately address the issue of antibiotic resistance, and if so, what would you recommend?





